TICKERNOMICS Sign up
Last Update: 2023-10-04 11:37:03
LANNETT CO INC ( LCI ) https://www.lannett.com
0.03USD
Sector:
Healthcare
Industry:
Drug Manufacturers-Specialty & Generic
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
14.73%
-98.64%
LCI
SPY
36.71%
-99.89%
LCI
SPY
70.96%
-99.86%
LCI
SPY
262.36%
-99.96%
LCI
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
0.28
-35.03
0.01
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.00
0.00
-0.00
-358.94
0.00
1.92
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-15.37
18.85
-5.64
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
6.7753
-11.76
-11.90
0.63
Other Earnings and Cash Flow Stats:
LANNETT CO INC ( LCI ) Net Income TTM ($MM) is -257.68
LANNETT CO INC ( LCI ) Operating Income TTM ($MM) is -67.90
LANNETT CO INC ( LCI ) Owners' Earnings Annual ($MM) is -70.88
LANNETT CO INC ( LCI ) Current Price to Owners' Earnings ratio is -0.24
LANNETT CO INC ( LCI ) EBITDA TTM ($MM) is -54.49
LANNETT CO INC ( LCI ) EBITDA Margin is -5.64%
Capital Allocation:
LANNETT CO INC ( LCI ) has paid 0.00 dividends per share and bought back -0.075835 million shares in the past 12 months
LANNETT CO INC ( LCI ) has reduced its debt by 621.971 million USD in the last 12 months
Capital Structure:
LANNETT CO INC ( LCI ) Interest-bearing Debt ($MM) as of last quarter is 11
LANNETT CO INC ( LCI ) Annual Working Capital Investments ($MM) are 16
LANNETT CO INC ( LCI ) Book Value ($MM) as of last quarter is -413
LANNETT CO INC ( LCI ) Debt/Capital as of last quarter is -3%
Other Balance Sheet Stats:
LANNETT CO INC ( LCI ) has 46 million in cash on hand as of last quarter
LANNETT CO INC ( LCI ) has 733 million of liabilities due within 12 months, and long term debt 1252 as of last quarter
LANNETT CO INC ( LCI ) has 10 common shares outstanding as of last quarter
LANNETT CO INC ( LCI ) has 0 million USD of preferred stock value
Academic Scores:
LANNETT CO INC ( LCI ) Altman Z-Score is -4.37 as of last quarter
LANNETT CO INC ( LCI ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
LANNETT CO INC ( LCI ) largest shareholder is Bridgeway Capital Management, LLC owning 29799 shares at 0.00 ($MM) value
Melissa Rewolinski(an insider) Bought 7789 shares of LANNETT CO INC ( LCI ) for the amount of $15266.44 on 2022-09-14
14.26% of LANNETT CO INC ( LCI ) is held by insiders, and 38.93% is held by institutions
LANNETT CO INC ( LCI ) went public on 1997-01-02
Other LANNETT CO INC ( LCI ) financial metrics:
FCF:-47.39
Unlevered Free Cash Flow:-67.72
EPS:-39.43
Operating Margin:-15.37
Gross Profit Margin:18.85
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:98.45
Beta:0.63
Buffet's Owners Earnings:-70.88
Price to Owner's Earnings:-0.24
About LANNETT CO INC ( LCI ) :
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's product portfolio includes Amphetamine IR tablets, Amphetamine ER capsules, Dicyclomine tablets, Fluphenazine tablets, Levothyroxine capsules, Methylphenidate CD capsules, Methylphenidate ER, Posaconazole DR tablets, Probenecid tablets, and Verapamil SR tablets, as well as Numbrino nasal solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, Sinotherapeutics, Respirent Pharmaceuticals Co., Ltd., HEC Pharm Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.